MYC and diffuse large B-cell lymphoma: Recently, the preliminary results of a prospective study treating patients with DLBCL or BL-INT with MYC rearrangement with six cycles of DA-EPOCH-R have been reported: at a median follow-up of 14 months, PFS is 79%, and OS is 77%.